|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||N/A|
|Expense Ratio (net)||N/A|
TORONTO , Feb. 6, 2019 /CNW/ - Abacus Health Products, Inc. (CSE: ABCS) ("Abacus" or the "Company") announced the launch of an advanced skincare line within its CBDMEDIC™ family of products for the treatment of acne, eczema, and itch and rash. This new line will include four topical products, including ointments, creams and facial cleansers, utilizing FDA-monograph active pharmaceutical ingredients, cannabinoids, and formulated with natural and organic ingredients. "We are tremendously proud to introduce the latest skincare products in our line of innovative topical treatments," said Perry Antelman , CEO of Abacus.
WOONSOCKET, RI and TORONTO , Jan. 30, 2019 /CNW/ - Abacus Health Products, Inc. (the "Company"), an Ontario corporation formerly known as World Wide Inc., is pleased to announce that it has completed its previously announced business combination (the "Business Combination") with Abacus Health Products, Inc. ("Abacus"), a Delaware corporation. In connection with the Business Combination, which closed on January 29, 2019 , Abacus completed a private placement offering of 4,000,000 subscription receipts (the "Subscription Receipts") at a price of US$3.75 per Subscription Receipt (the "Issue Price") for aggregate gross proceeds in the amount of US$15,000,000 (the "Offering"). The Subordinate Voting Shares will trade in Canadian dollars.